US LNG exports surge but will buyers in China turn up?
Valeria Gutowski, the Chief Accounting Officer of Enfusion , Inc. (NYSE:ENFN), recently sold 542 shares of the company’s Class A common stock. The shares were sold at a weighted average price of $11.375, totaling approximately $6,165. This transaction was executed on March 5, 2025. The sale comes as Enfusion’s stock trades near its 52-week high of $11.80, having gained nearly 40% over the past six months. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 3.42 and commands a market capitalization of $1.46 billion.
The sale was conducted to cover tax withholding obligations related to the issuance of shares and does not represent discretionary trading by Gutowski. Following the transaction, she holds 47,622 shares directly. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with 12 additional ProTips available to subscribers covering everything from earnings growth to valuation metrics.
In other recent news, Enfusion Inc has been a focal point due to its fourth-quarter earnings announcement and acquisition agreement with Clearwater Analytics. The company’s latest financial performance data was released, although Stifel did not elaborate on the implications for the stock’s valuation, as the acquisition agreement sets a clear expectation for its value. The acquisition deal, priced at $11.25 per share, has influenced several analyst ratings and price targets. Stifel analysts downgraded Enfusion from Buy to Hold, aligning their price target with the acquisition price of $11.25, which they consider a fair offer for shareholders.
Morgan Stanley (NYSE:MS) also adjusted its stance, downgrading Enfusion from Overweight to Equal-weight while raising the price target to $11.25, reflecting the acquisition price. The analysts at Morgan Stanley noted that the acquisition could expedite value realization for shareholders and address previous concerns about the company’s market position. The acquisition agreement represents a significant transition for Enfusion, with analysts seeing little deviation from the acquisition valuation in the near term. The situation continues to unfold as investors keep a close watch on the developments surrounding Enfusion’s acquisition by Clearwater Analytics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.